Indicators
Indicators
Value
Direction
MACD(12,26,9)
0.045
Neutral
RSI(14)
47.458
Neutral
STOCH(KDJ)(9,3,3)
66.971
Neutral
ATR(14)
0.086
Low Volatility
CCI(14)
194.160
Buy
Williams %R
34.783
Buy
TRIX(12,20)
-0.738
Sell
StochRSI(14)
74.665
Sell
BioRestorative Therapies Inc
BRTX1.150USD
-0.030-2.54%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
9.17MMarket Cap
LossP/E TTM
TradingKey Stock Score
Overall Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Peer Comparison
TradingKey Stock Score of BioRestorative Therapies Inc
Currency: USD Updated: 2025-12-19Key Insights
BioRestorative Therapies Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 165/404 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 13.00.In the medium term, the stock price is expected to trend down.Despite an average stock market performance over the past month, the company shows strong technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
BioRestorative Therapies Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
2
analysts
Buy
Current Rating
13.000
Target Price
+1103.70%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
BioRestorative Therapies Inc Highlights
StrengthsRisks
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 234.72% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 401.00K.
Fairly Valued
The company’s latest PE is -0.79, at a medium 3-year percentile range.
Held by The Vanguard
Star Investor The Vanguard holds 88.78K shares of this stock.
Financial Health
Currency: USD Updated: 2025-12-19The current financial score of BioRestorative Therapies Inc is 5.41, ranking 381/404 in the Biotechnology & Medical Research industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 11.80K, representing a year-over-year decrease of 94.95%, while its net profit experienced a year-over-year decrease of 178.38%.
Score
Financials
4.67
Key Metrics
Cash and cash equivalents
Total assets
Total liabilities
Free cash flow
Relevant data have not been disclosed by the company yet.
Quality of Earnings
7.61
Operational Efficiency
2.83
Growth Potential
4.85
Shareholder Returns
7.07
BioRestorative Therapies Inc's Company Valuation
Currency: USD Updated: 2025-12-19The current valuation score of BioRestorative Therapies Inc is 7.70, ranking 95/404 in the Biotechnology & Medical Research industry. Its current P/E ratio is -0.79, which is -3556.98% below the recent high of 27.27 and -222.25% above the recent low of -2.54.
Score
Valuation Dimensions
P/E
P/B
P/S
P/CF
Industry Ranking 165/404
Relevant data have not been disclosed by the company yet.
Earnings Forecast
Currency: USD Updated: 2025-12-19The current earnings forecast score of BioRestorative Therapies Inc is 8.00, ranking 168/404 in the Biotechnology & Medical Research industry. The average price target for BioRestorative Therapies Inc is 13.00, with a high of 18.00 and a low of 8.00.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Analyst Rating
Based on
2
analysts
Buy
Current Rating
13.000
Target Price
+1103.70%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
534
Total
6
Median
6
Average
Company name
Ratings
Analysts
BioRestorative Therapies Inc
BRTX
2
CRISPR Therapeutics AG
CRSP
30
Intellia Therapeutics Inc
NTLA
25
IQVIA Holdings Inc
IQV
25
argenx SE
ARGX
25
Ionis Pharmaceuticals Inc
IONS
24
1
2
3
...
107
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Relevant data have not been disclosed by the company yet.
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Price Momentum
Currency: USD Updated: 2025-12-19The current price momentum score of BioRestorative Therapies Inc is 6.27, ranking 279/404 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 1.26 and the support level at 1.01, making it suitable for range-bound swing trading.
Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Indicators
The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.
This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.
Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.
Moving Average
Indicators
Value
Direction
MA5
1.124
Buy
MA10
1.108
Buy
MA20
1.095
Buy
MA50
1.325
Sell
MA100
1.426
Sell
MA200
1.565
Sell
Institutional Confidence
Currency: USD Updated: 2025-12-19The current institutional shareholding score of BioRestorative Therapies Inc is 3.00, ranking 197/404 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 10.80%, representing a quarter-over-quarter decrease of 13.26%. The largest institutional shareholder is The Vanguard, holding a total of 88.78K shares, representing 1.00% of shares outstanding, with 132.82% increase in holdings.
Score
Institutional Shareholding
Relevant data have not been disclosed by the company yet.
Shareholder Activity
Name
Shares Held
Chg %
Broadrick (Dale)
Hale (Morrison Todd)
Auctus Fund Management, L.L.C.
Alstodt (Lance)
Silva (Francisco)
Geode Capital Management, L.L.C.
Wealth Alliance
StoneX Group Inc.
1
2
Risk Assessment
Currency: USD Updated: 2025-12-19The current risk assessment score of BioRestorative Therapies Inc is 2.70, ranking 215/404 in the Biotechnology & Medical Research industry. The company's beta value is 0.16. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.
Score
Beta vs S&P 500 index
0.16
VaR
+9.09%
240-Day Maximum Drawdown
+58.23%
240-Day Volatility
+90.38%
Return
Best Daily Return
60 days
+15.32%
120 days
+17.24%
5 years
+102.41%
Worst Daily Return
60 days
-22.38%
120 days
-22.38%
5 years
-53.66%
Sharpe Ratio
60 days
-0.92
120 days
-0.81
5 years
-0.18
Risk Assessment
Maximum Drawdown
240 days
+58.23%
3 years
+83.98%
5 years
--
Return-to-Drawdown Ratio
240 days
-0.48
3 years
-0.25
5 years
--
Skewness
240 days
+0.07
3 years
+0.20
5 years
+2.42
Volatility
Realised Volatility
240 days
+90.38%
5 years
--
Standardised True Range
240 days
+10.51%
5 years
--
Downside Risk-Adjusted Return
120 days
-112.03%
240 days
-112.03%
Maximum Daily Upside Volatility
60 days
+52.76%
Maximum Daily Downside Volatility
60 days
+74.12%
Liquidity
Average Turnover Rate
60 days
+1.99%
120 days
+1.24%
5 years
--
Turnover Deviation
20 days
-84.18%
60 days
-71.75%
120 days
-82.41%
Peer Comparison
Biotechnology & Medical Research
BioRestorative Therapies Inc
BRTX
5.93 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Amicus Therapeutics Inc
FOLD
8.80 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Krystal Biotech Inc
KRYS
8.42 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Charles River Laboratories International Inc
CRL
8.41 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
Madrigal Pharmaceuticals Inc
MDGL
8.35 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
IQVIA Holdings Inc
IQV
8.30 /10
Score
Financial Health
Valuation Dimensions
Earnings Forecast
Price Momentum
Institutional Confidence
Risk Assessment
View more
FAQs
How does TradingKey generate the Stock Score of BioRestorative Therapies Inc?
The TradingKey Stock Score provides a comprehensive assessment of BioRestorative Therapies Inc based on 34 indicators derived from over 100 underlying data points. These indicators are categorised into six key dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and risk assessment, collectively providing investors with a thorough analysis of BioRestorative Therapies Inc’s performance and outlook.
How do we generate the financial health score of BioRestorative Therapies Inc?
To generate the financial health score of BioRestorative Therapies Inc, we analyse various key financial indicators across several core dimensions, including financial fundamentals, earnings quality, operational efficiency, growth potential, and shareholder returns. By integrating these comprehensive data, the financial health score not only reflects BioRestorative Therapies Inc's overall stability, operational efficiency, and growth potential but also captures the investment returns delivered to shareholders. This score aims to support rational decision-making for investors and other stakeholders. A higher score indicates a better financial health of BioRestorative Therapies Inc.
How do we generate the company valuation score of BioRestorative Therapies Inc?
To generate the company valuation score of BioRestorative Therapies Inc, we use several key financial ratios, including P/E, P/B, P/S, and P/CF. These metrics compare BioRestorative Therapies Inc’s market value to its earnings, assets, sales, and cash flow, serving as core indicators for assessing company value. By analysing these ratios in an all-round manner, the valuation score reflects not only the market’s current perception of BioRestorative Therapies Inc’s value but also its future profitability and growth potential, thereby supporting more informed investment decisions. A higher score indicates a fairer valuation of BioRestorative Therapies Inc.
How do we generate the earnings forecast score of BioRestorative Therapies Inc?
To calculate the earnings forecast score of BioRestorative Therapies Inc, we consider various key indicators such as analyst ratings, financial forecasts, support and resistance levels, and peer comparisons:Current ratings and price targets directly reflect analysts’ expectations, while the upside space indicates their views on the stock’s growth potential.Financial metrics like earnings per share (EPS), revenue, net income, and earnings before interest and taxes (EBIT) are core measures for assessing profitability.By analysing the high, median, and low ranges of the target price, we can identify price trends and determine key support and resistance levels.Comparing these indicators against peers provides context for the stock’s performance and helps
anchor more realistic expectations.These factors together form a comprehensive earnings forecast score that accurately reflects the stock’s expected financial performance and growth potential. A higher score suggests that analysts have a more optimistic outlook on BioRestorative Therapies Inc’s future.
How do we generate the price momentum score of BioRestorative Therapies Inc?
When generating the price momentum score for BioRestorative Therapies Inc, we examine momentum indicators including support and resistance levels as well as volume metrics.Support levels represent price points where buying interest is strong enough to prevent further declines, while resistance levels indicate prices where selling pressure may hinder upward movement. By analysing typical price volume alongside total volume, we assess overall market activity and liquidity. These indicators help identify price trends and potential shifts, enabling more accurate predictions of future earnings.This comprehensive approach can reflect market sentiment and enable rational forecasts of BioRestorative Therapies Inc’s prices. A higher score indicates a more stable short-term price trend for BioRestorative Therapies Inc.
How do we generate the institutional confidence score of BioRestorative Therapies Inc?
To generate the institutional confidence score of BioRestorative Therapies Inc, we analyse both the proportion of shares held by institutions and the number of shares they own. A higher institutional ownership percentage indicates strong confidence of professional investors, which is generally a positive signal about BioRestorative Therapies Inc’s potential. By examining the number of shares held, we gain deeper insight into institutions’ commitment and attitude toward the stock, as institutional investors typically conduct thorough analysis before making investment decisions. Understanding institutional confidence helps us refine earnings forecasts and provides a more reliable perspective on the company’s future performance and market stability. A higher score indicates greater institutional endorsement of BioRestorative Therapies Inc.
How do we generate the risk management score of BioRestorative Therapies Inc?
To assess the risk management score of BioRestorative Therapies Inc, we examine multiple key indicators related to returns, risk, volatility, and liquidity.The highest and lowest daily returns reflect the potential size of gains and losses, while the Sharpe ratio measures risk-adjusted return performance. On the risk side, we analyse maximum drawdown and the return-to-drawdown ratio to identify extreme loss scenarios. Skewness helps assess the distribution of returns and whether performance may be biased. Volatility indicators—such as realised volatility and standardised true range—reveal price fluctuations. Downside risk-adjusted returns provide insight into potential losses and gains. Lastly, liquidity metrics like average turnover rate and turnover deviation indicate how actively the stock is traded.These indicators together provide a multi-dimensional understanding of BioRestorative Therapies Inc’s risk-return profile, serving as core factors of the risk management score. A higher score indicates lower risk on the side of BioRestorative Therapies Inc.
